Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CLEO Diagnostics Ltd ( (AU:COV) ) has shared an announcement.
Cleo Diagnostics has completed optimisation of the biomarker panel for its Pre-Surgical Ovarian Cancer Test, expanding it from five to eight markers to enhance analytical robustness, inter-assay reproducibility and compatibility with commercial manufacturing. The panel is tailored for the Ella platform’s microfluidic cartridges, allowing simultaneous measurement of multiple biomarkers without sacrificing workflow efficiency or sample usage.
By broadening the panel, the company reduces dependence on any single analyte and lowers technical risk in early-stage assay production, strengthening reliability ahead of analytical validation. Cleo has aligned the optimised panel with an experienced manufacturing partner, with a binding kit-manufacturing agreement expected shortly to enable immediate production of validation lots and support its planned FDA 510(k) submission and entry into the U.S. market.
The most recent analyst rating on (AU:COV) stock is a Buy with a A$1.26 price target. To see the full list of analyst forecasts on CLEO Diagnostics Ltd stock, see the AU:COV Stock Forecast page.
More about CLEO Diagnostics Ltd
Cleo Diagnostics Ltd is an Australian ovarian cancer diagnostics company focused on developing a pre-surgical blood test to distinguish benign from malignant ovarian disease. Its technology is built around a patented CXCL10 biomarker and is being developed for use on the high-throughput Ella immunoassay platform to enable scalable global deployment, with a clear focus on the U.S. market and regulatory clearance.
Average Trading Volume: 318,479
Technical Sentiment Signal: Hold
Current Market Cap: A$65.69M
See more data about COV stock on TipRanks’ Stock Analysis page.